Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genmab ( (GMAB) ) has issued an announcement.
Genmab A/S, the Danish antibody-focused biotechnology group, held its Annual General Meeting (AGM) on March 19, 2026 in Copenhagen, where shareholders approved the audited Annual Report for 2025 and the company’s Compensation Report. The AGM also confirmed that the 2025 profit of USD 963 million will be carried forward into retained earnings, underscoring Genmab’s continued profitability as it advances its late-stage pipeline.
Shareholders re-elected six incumbent board members and Deloitte as the company’s auditor, signaling continuity in governance and oversight. The meeting further approved a reduction of Genmab’s share capital through the cancellation of treasury shares, a move that can enhance capital efficiency, while the proposal on 2026 board remuneration was withdrawn and will be resubmitted for shareholder consideration at a later date.
The most recent analyst rating on (GMAB) stock is a Hold with a $29.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, it has built a broad portfolio of antibody-based therapeutic formats, including bispecifics, antibody–drug conjugates and immune-modulating antibodies, powering eight approved medicines and a strong late-stage clinical pipeline.
Average Trading Volume: 1,704,640
Technical Sentiment Signal: Sell
Current Market Cap: $15.89B
For detailed information about GMAB stock, go to TipRanks’ Stock Analysis page.